Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy
- PMID: 30370355
- PMCID: PMC6200875
- DOI: 10.1016/j.adro.2018.05.007
Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy
Abstract
Purpose: This study aimed to explore the associations between dose-volume parameters of localized breast irradiation, longitudinal interleukin-6 soluble receptor (sIL-6R), and leukocyte counts as markers of an immune-mediated response and fatigue as a centrally-driven behavior.
Methods and materials: This prospective cohort study recruited 100 women who were diagnosed with stage 0-IIIa breast cancer, prescribed 40 Gy in 15 fractions over 3 weeks adjuvant radiation therapy, and had no prior or concurrent chemotherapy. Dose-volume parameters were derived from treatment plans and related to serum sIL-6R concentrations, leukocyte counts, and a validated measure of self-reported fatigue at baseline, after 10 and 15 fractions, and 4 weeks after radiation therapy.
Results: sIL-6R concertation was significantly higher in patients with a total volume of tissue irradiated within the 50% isodose >2040 cm3 (P = .003). When controlling for body mass index, this result only remained significant after treatment. The volume of liver irradiated within the 10% isodose correlated with the sIL-6R concentration during and after radiation therapy (ρ = .3-.4; P = .03-.007). The 38% of the cohort that was classified as fatigued had a higher mean sIL-6sR concentration at all observation points, but the differences were only statistically significant during radiation therapy: Mean (standard deviation [SD]) after 15 fractions for fatigued patients was 47.6 ng/dL (11.2 SD) versus 41.6 ng/dL (11.4 SD) for nonfatigued patients (P = .01). Cohort leukocyte counts and leukocyte subsets decreased consistently from baseline and the values for the fatigued group were 4% lower at baseline and between 7% and 9% lower during and after treatment compared with those of the nonfatigued group but the differences were not statistically significant.
Conclusions: This is the first study to show that localized irradiation induces increased systemic sIL-6R during treatment in participants who reported elevated levels of fatigue before, during, and after treatment. This behavioral response appears to reflect a variation in innate host immunity, which then mediates the cellular and/or psychological stress of radiation therapy.
Similar articles
-
Inflammatory biomarkers for persistent fatigue in breast cancer survivors.Clin Cancer Res. 2006 May 1;12(9):2759-66. doi: 10.1158/1078-0432.CCR-05-2398. Clin Cancer Res. 2006. PMID: 16675568
-
Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.Transplantation. 1996 Jul 15;62(1):138-42. doi: 10.1097/00007890-199607150-00029. Transplantation. 1996. PMID: 8693533
-
Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer.Support Care Cancer. 2013 Jan;21(1):173-81. doi: 10.1007/s00520-012-1508-6. Epub 2012 May 28. Support Care Cancer. 2013. PMID: 22644262
-
[Increased serum IL-6 and soluble IL-6 receptor in breast cancer patients after radiotherapy are correlated with proportions of immune cells].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019 Aug;35(8):738-743. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019. PMID: 31638571 Chinese.
-
Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder.Arch Intern Med. 2006 Sep 18;166(16):1725-31. doi: 10.1001/archinte.166.16.1725. Arch Intern Med. 2006. PMID: 16983050
References
-
- Noal S., Levy C., Hardouin A. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2011;81:795–803. - PubMed
-
- Herskind C., Bamberg M., Rodemann H.P. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol. 1998;174:12–15. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials